EUVIMEDEUVIMED entdecken
Open Access

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations

Yifang Eva Pan iD, Annette Hood, Hiba Ahmad, Gary Altwerger

Annals of Pharmacotherapy · 2023

DOI: 10.1177/10600280221149136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Yifang Eva Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data regarding the use of poly (ADP-ribose) polymerase (PARP) inhibitors in recurrent ovarian cancer patients with non-BRCA homologous recombination (HR) mutations or somatic BRCA mutations are lacking.

Objective

The purpose of our study is to evaluate the response rate, duration of treatment, time to progression (TTP), and toxicities of olaparib, niraparib, and rucaparib in somatic BRCAm and non-BRCA HR-mutated patients.

Methods

This was a retrospective study using the electronic medical record to identify patients across our health system who were initiated on a PARP inhibitor for ovarian cancer between December 2014 and December 2019. Patients were screened for the presence of a somatic BRCA1/2 mutation or a mutation in non-BRCA HR genes. Data were collected via chart review.

Results

For the efficacy analysis, 8 patients had somatic BRCA mutations and 12 patients had HR mutations. The overall response rate (ORR) was 50% for BRCA-mutated (BRCAm) patients and 9.1% for non-BRCA HR-mutated (non-BRCA HRm) patients. 72.7% of patients with non-BRCA HR mutations had stable disease. The duration of therapy ranged from 2 to 66 months. The median TTP was 9.5 months. Overall, 66.7% of patients in the entire cohort started on a reduced dose of PARP inhibitor. Dose reductions due to AEs were observed in 52.4% of patients, while AEs requiring treatment interruption occurred in 61.9%. Conclusion and Relevance: We found that PARP inhibitors provided stable disease in a high proportion of recurrent ovarian cancer patients who had pathogenic HR mutations, with toxicities comparable to major trials. Patients with non-BRCA HR and somatic BRCA mutations could benefit from PARP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsHumansFemalePoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinRetrospective StudiesBRCA2 ProteinCarcinoma, Ovarian EpithelialMutationHomologous Recombination

Stichwörter der Autor:innen

homologous recombination deficiencyniraparibolaparibovarian cancerrucaparibsomatic BRCA mutations

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA.
  • University of Colorado Hospital, Aurora, CO, USA.
  • Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Yifang Eva Pan

Förderung

  • NICHD NIH HHS

Zitieren

APA

Pan, Y. E., Hood, A., Ahmad, H., & Altwerger, G. (2023). Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280221149136

Vancouver

Pan YE, Hood A, Ahmad H, Altwerger G. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280221149136

BibTeX
@article{Pan2023,
  author = {Pan, Yifang Eva and Hood, Annette and Ahmad, Hiba and Altwerger, Gary},
  title = {Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations},
  journal = {Annals of Pharmacotherapy},
  year = {2023},
  doi = {10.1177/10600280221149136}
}
Kostenlos starten →